<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04972552</url>
  </required_header>
  <id_info>
    <org_study_id>21-34366</org_study_id>
    <nct_id>NCT04972552</nct_id>
  </id_info>
  <brief_title>Watermelon/UBIQuinone Study</brief_title>
  <acronym>WUBI-Q</acronym>
  <official_title>Watermelon/UBIQuinone Study (WUBI-Q Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the proposed pilot trial is to determine the feasibility and safety of&#xD;
      increasing watermelon consumption, with or without coenzyme Q supplementation in patients&#xD;
      after kidney transplantation on kidney function and urinary protein excretion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While many observational studies have examined the effects of consuming watermelon in&#xD;
      patients without chronic kidney disease, there have been few studies on the consumption of a&#xD;
      diet high in watermelon as a means of improving kidney function or reducing protein in the&#xD;
      urine. Coenzyme Q is also recognized as a supplement that has benefits for heart health and&#xD;
      has anti-oxidative effects, but whether it could be used to improve kidney function or reduce&#xD;
      protein in the urine has not been thoroughly examined, especially in the kidney transplant&#xD;
      population. The objective of the proposed pilot trial is to determine the feasibility and&#xD;
      safety of increasing watermelon consumption, with or without coenzyme Q supplementation in&#xD;
      patients after kidney transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>2x2 placebo-controlled factorial trial</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Randomization will be performed by a pharmacy and investigators will not know the assignment until trial completion.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who complete the study after randomized assignment</measure>
    <time_frame>Measured at the 20 weeks mark</time_frame>
    <description>We will determine the number of patients who drop out of the study following randomized assignment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who develop adverse safety events (including low systolic blood pressure or hyperkalemia) during participation in the study</measure>
    <time_frame>Measured from 0-20 weeks</time_frame>
    <description>We will measure the number of patients who develop low blood pressure and high potassium levels (hyperkalemia) following randomized assignment. Low blood pressure will be defined as systolic blood pressure &lt; 90 mmHg; hyperkalemia will be defined as serum potassium &gt; 5.5 meq/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who are adherent by pill count to coenzyme Q10</measure>
    <time_frame>Measures from 0-20 weeks</time_frame>
    <description>Pill count adherence will be computed as the percentage of the number of prescribed pills corrected for the number of returned pills divided by the period (in days) multiplied by 100%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in weight from baseline to 20 weeks</measure>
    <time_frame>Baseline to 20 weeks</time_frame>
    <description>We will check for a change in weight, measured in kg, at the start and end of the intervention period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in amount of protein excretion in the urine over a 20-week period</measure>
    <time_frame>Baseline to 20 weeks</time_frame>
    <description>We will check for a change in urine protein/creatinine ratio (g/g) at the start and end of the intervention period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in kidney function (eGFR) over a 20 week period</measure>
    <time_frame>Baseline to 20 weeks</time_frame>
    <description>We will assess changes in patient kidney function based on eGFR measured by CKD-EPI equation in mL/min/1.73 m2 throughout the intervention period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of interstitial fibrosis and tubular atrophy</measure>
    <time_frame>At 20 weeks (cross-sectional)</time_frame>
    <description>We will compare the degree of interstitial fibrosis or tubular atrophy (as a percentage on a biopsy specimen) based on kidney biopsy results.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Watermelon Diet &amp; Coenzyme Q10</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>800-1200 mg of coenzyme Q10 daily plus diet high in watermelon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Diet &amp; Coenzyme Q10</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>800-1200 mg of coenzyme Q10 daily plus no watermelon in diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Watermelon Diet &amp; Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pill plus diet high in watermelon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Diet &amp; Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pill plus no watermelon in diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>coenzyme Q10</intervention_name>
    <description>Participants will take 800-1200 mg of coenzyme Q10 capsule per day</description>
    <arm_group_label>Usual Diet &amp; Coenzyme Q10</arm_group_label>
    <arm_group_label>Watermelon Diet &amp; Coenzyme Q10</arm_group_label>
    <other_name>CoQ10</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Watermelon diet</intervention_name>
    <description>Participants will be asked to eat watermelon at a minimum of one meal per day 3-5 days a week</description>
    <arm_group_label>Watermelon Diet &amp; Coenzyme Q10</arm_group_label>
    <arm_group_label>Watermelon Diet &amp; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Diet</intervention_name>
    <description>Participants will be asked to eat a usual diet but not eat any watermelon as part of their usual diet</description>
    <arm_group_label>Usual Diet &amp; Coenzyme Q10</arm_group_label>
    <arm_group_label>Usual Diet &amp; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will be asked to take 800-1200 mg of a placebo capsule per day</description>
    <arm_group_label>Usual Diet &amp; Placebo</arm_group_label>
    <arm_group_label>Watermelon Diet &amp; Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Received a kidney transplant in the last four weeks&#xD;
&#xD;
          -  Potassium &lt; 4.8 at time of randomization (not having high potassium already)&#xD;
&#xD;
          -  History of hemodialysis dependency (and not peritoneal dialysis) prior to kidney&#xD;
             transplant&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Not currently consuming a high-watermelon diet or taking co-enzyme Q10&#xD;
&#xD;
          -  Not underweight (body mass index &lt;19 kg/m2)&#xD;
&#xD;
          -  Receiving standard immunosuppression regimen (mycophenolate, and tacrolimus)&#xD;
&#xD;
          -  Not enrolled in any other interventional trial&#xD;
&#xD;
          -  Planning to return for follow-up at UCSF (or willing to return for study visits)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt; 18 years of age at the time of transplant&#xD;
&#xD;
          -  Potassium &gt;=4.8 meq/L at randomization&#xD;
&#xD;
          -  History of peritoneal dialysis dependency or preemptive transplantation&#xD;
&#xD;
          -  Unable to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elaine Ku</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elaine Ku, MD, MAS</last_name>
    <phone>415-514-0989</phone>
    <email>elaine.ku@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Divya Seth, BA</last_name>
    <phone>415-514-0989</phone>
    <email>divya.seth@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Elaine Ku, MD</last_name>
      <email>elaine.ku@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Deborah Adey, MD</last_name>
      <email>deborah.adey@ucsf.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lum T, Connolly M, Marx A, Beidler J, Hooshmand S, Kern M, Liu C, Hong MY. Effects of Fresh Watermelon Consumption on the Acute Satiety Response and Cardiometabolic Risk Factors in Overweight and Obese Adults. Nutrients. 2019 Mar 12;11(3). pii: E595. doi: 10.3390/nu11030595.</citation>
    <PMID>30870970</PMID>
  </reference>
  <reference>
    <citation>Hong MY, Hartig N, Kaufman K, Hooshmand S, Figueroa A, Kern M. Watermelon consumption improves inflammation and antioxidant capacity in rats fed an atherogenic diet. Nutr Res. 2015 Mar;35(3):251-8. doi: 10.1016/j.nutres.2014.12.005. Epub 2015 Jan 3.</citation>
    <PMID>25631716</PMID>
  </reference>
  <reference>
    <citation>Figueroa A, Wong A, Jaime SJ, Gonzales JU. Influence of L-citrulline and watermelon supplementation on vascular function and exercise performance. Curr Opin Clin Nutr Metab Care. 2017 Jan;20(1):92-98. Review.</citation>
    <PMID>27749691</PMID>
  </reference>
  <reference>
    <citation>Figueroa A, Sanchez-Gonzalez MA, Wong A, Arjmandi BH. Watermelon extract supplementation reduces ankle blood pressure and carotid augmentation index in obese adults with prehypertension or hypertension. Am J Hypertens. 2012 Jun;25(6):640-3. doi: 10.1038/ajh.2012.20. Epub 2012 Mar 8.</citation>
    <PMID>22402472</PMID>
  </reference>
  <reference>
    <citation>Rivara MB, Yeung CK, Robinson-Cohen C, Phillips BR, Ruzinski J, Rock D, Linke L, Shen DD, Ikizler TA, Himmelfarb J. Effect of Coenzyme Q(10) on Biomarkers of Oxidative Stress and Cardiac Function in Hemodialysis Patients: The CoQ(10) Biomarker Trial. Am J Kidney Dis. 2017 Mar;69(3):389-399. doi: 10.1053/j.ajkd.2016.08.041. Epub 2016 Dec 4.</citation>
    <PMID>27927588</PMID>
  </reference>
  <reference>
    <citation>Yu JH, Lim SW, Luo K, Cui S, Quan Y, Shin YJ, Lee KE, Kim HL, Ko EJ, Chung BH, Kim JH, Chung SJ, Yang CW. Coenzyme Q(10) alleviates tacrolimus-induced mitochondrial dysfunction in kidney. FASEB J. 2019 Nov;33(11):12288-12298. doi: 10.1096/fj.201900386RR. Epub 2019 Aug 20.</citation>
    <PMID>31431058</PMID>
  </reference>
  <reference>
    <citation>Długosz A, Kuźniar J, Sawicka E, Marchewka Z, Lembas-Bogaczyk J, Sajewicz W, Boratyńska M. Oxidative stress and coenzyme Q10 supplementation in renal transplant recipients. Int Urol Nephrol. 2004;36(2):253-8.</citation>
    <PMID>15368706</PMID>
  </reference>
  <reference>
    <citation>Yeung CK, Billings FT 4th, Claessens AJ, Roshanravan B, Linke L, Sundell MB, Ahmad S, Shao B, Shen DD, Ikizler TA, Himmelfarb J. Coenzyme Q10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress. BMC Nephrol. 2015 Nov 3;16:183. doi: 10.1186/s12882-015-0178-2.</citation>
    <PMID>26531095</PMID>
  </reference>
  <reference>
    <citation>Shanely RA, Nieman DC, Perkins-Veazie P, Henson DA, Meaney MP, Knab AM, Cialdell-Kam L. Comparison of Watermelon and Carbohydrate Beverage on Exercise-Induced Alterations in Systemic Inflammation, Immune Dysfunction, and Plasma Antioxidant Capacity. Nutrients. 2016 Aug 22;8(8). pii: E518. doi: 10.3390/nu8080518.</citation>
    <PMID>27556488</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 2, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ubiquinone</mesh_term>
    <mesh_term>Coenzyme Q10</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

